The comparison of Zataria multiflora vaginal cream and Metronidazol oral tablet effect on the therapy results of trichomona vaginalis and bacterial vaginosis in reproductive women

The comparison of Zataria multiflora vaginal cream and Metronidazol oral tablet effect on the therapy results of trichomona vaginalis and bacterial vaginosis in women refered to selection departments of Shiraz medical science university

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110291548N12

Enrollment

420

Registered

2011-11-21

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaginos bactrial and trichomona vaginalis. n76.8

Interventions

Intervention 1: vaginal cream plasbo zataria multiflora vaginal crem zataria multiflora 0.1 % , 50 g , 7 days , 1 applicator 5 g oral tablet plasbo metronidazol. Intervention 2: oral tablet metronid

Treatment - Drugs

vaginal cream plasbo zataria multiflora vaginal crem zataria multiflora 0.1 % , 50 g , 7 days , 1 applicator 5 g oral tablet plasbo metronidazol

oral tablet metronidazol , 250 mg , 7days q12h two tablet , tehran chemic company

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Entering criteria into the study were as fallowing : Tending to cooperate ; Reproductive age women Existing criteria are fallowing entries : Having abnormal uterus bleeding ; Frequently vulvovaginits ; pregnancy ; Mensturation ; Lactating ; Use of vaginal douches frequently, consuming remedy for treatment in 3 recent months ; Consumig alcohol and anti coagulation remedies and recent consuming anti-parasite remedy, anti-biotic, weakening remedy of safety system and vaginalis remedy ;Multi partner ; Stricken to specific diseases like liver diseases ,kidney diseases and central chords system diseases ,blood dyscrasi ,diabetes ,impair of safety system, known sexual transmitted diseases ; President of allergy Labiants in form of larder and locally ; President of allergy in using metronidazol tablet

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Gram stian and- wet smear - clinical signs. Timepoint: befor intervention and 2 week after intervention. Method of measurement: question sheet.	—

Secondary

Measure	Time frame
Side effects. Timepoint: 2 week after intervention. Method of measurement: question sheet.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Abdali

Shiraz University of Medical Sciences

abdali-kh@yahoo.com+98 917 717 0129

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026